Davenport & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Davenport & Co’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,500	Closed	-$7.31K	–	1269
2025 Q2	$7.31K	Hold	13,500	–	–	﹤0.01%	1201
2025 Q1	$8.85K	Hold	13,500	–	–	﹤0.01%	1168
2024 Q4	$13.8K	Hold	13,500	–	–	﹤0.01%	1147
2024 Q3	$11.7K	Hold	13,500	–	–	﹤0.01%	1138
2024 Q2	$4.84K	Hold	13,500	–	–	﹤0.01%	1110
2024 Q1	$9.05K	Hold	13,500	–	–	﹤0.01%	1105
2023 Q4	$7.33K	Sell	13,500 -33,600	-71%	-$15.5K	﹤0.01%	1061
2023 Q3	$28.3K	Sell	47,100 -21,200	-31%	-$22.7K	﹤0.01%	1042
2023 Q2	$88.8K	Sell	68,300 -9,700	-12%	-$13.3K	﹤0.01%	1038
2023 Q1	$137K	Sell	78,000 -100	-0.1%	-$285	﹤0.01%	1010
2022 Q4	$245K	Sell	78,100 -35,400	-31%	-$137K	﹤0.01%	879
2022 Q3	$556K	Buy	113,500 +7,800	+7%	+$40.1K	﹤0.01%	647
2022 Q2	$438K	Buy	105,700 +1,000	+1%	+$4.32K	﹤0.01%	716
2022 Q1	$608K	Sell	104,700 -1,000	-0.9%	-$5.95K	﹤0.01%	685
2021 Q4	$793K	Sell	105,700 -22,000	-17%	-$191K	0.01%	621
2021 Q3	$1.15M	Sell	127,700 -500	-0.4%	-$4.94K	0.01%	512
2021 Q2	$1.53M	Hold	128,200	–	–	0.01%	386
2021 Q1	$1.61M	Sell	128,200 -3,645	-3%	-$49.1K	0.02%	316
2020 Q4	$2.06M	Sell	131,845 -4,000	-3%	-$46.9K	0.02%	272
2020 Q3	$1.28M	Sell	135,845 -15,200	-10%	-$164K	0.01%	303
2020 Q2	$1.35M	Sell	151,045 -29,745	-16%	-$276K	0.02%	282
2020 Q1	$1.15M	Buy	180,790 +39,515	+28%	+$293K	0.02%	275
2019 Q4	$1.18M	Sell	141,275 -283,526	-67%	-$2.61M	0.01%	316
2019 Q3	$4.58M	Hold	424,801	–	–	0.05%	175
2019 Q2	$4.58M	Buy	424,801 +355,876	+516%	+$3.78M	0.05%	173
2019 Q1	$658K	Buy	68,925 +900	+1%	+$9.19K	0.01%	370
2018 Q4	$781K	Sell	68,025 -101,085	-60%	-$1.26M	0.01%	320
2018 Q3	$2.87M	Buy	169,110 +103,510	+158%	+$1.57M	0.03%	210
2018 Q2	$932K	Buy	65,600 +100	+0.2%	+$1.66K	0.01%	330
2018 Q1	$1.24M	Buy	65,500 +15,500	+31%	+$331K	0.02%	283
2017 Q4	$820K	Hold	50,000	–	–	0.01%	347
2017 Q3	$750K	Hold	50,000	–	–	0.01%	348
2017 Q2	$440K	Hold	50,000	–	–	0.01%	458
2017 Q1	$153K	Hold	50,000	–	–	﹤0.01%	601
2016 Q4	$152K	Sell	50,000 -300	-0.6%	-$1.09K	﹤0.01%	601
2016 Q3	$233K	Buy	50,300 +4,500	+10%	+$22.9K	﹤0.01%	538
2016 Q2	$265K	Hold	45,800	–	–	﹤0.01%	492
2016 Q1	$277K	Hold	45,800	–	–	﹤0.01%	475
2015 Q4	$418K	Sell	45,800 -24,900	-35%	-$192K	0.01%	394
2015 Q3	$399K	Sell	70,700 -9,359	-12%	-$77.2K	0.01%	394
2015 Q2	$888K	Hold	80,059	–	–	0.01%	297
2015 Q1	$1.26M	Buy	+80,059	New	+$1.24M	0.02%	270

Other funds holding SGMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Davenport & Co's SGMO Position: Q3 2025 in Review

Davenport & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 13,500 shares — an estimated $7.31K sold.

Davenport & Co first reported a position in SGMO in Q1 2015 and held it in 42 quarters. The position peaked at $4.58M in Q3 2019. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

Davenport & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
Davenport & Co sold 13,500 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $7.31K.
Davenport & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2015 and held it in 42 quarters.
Davenport & Co's SANGAMO THERAPEUTICS INC position peaked at $4.58M in Q3 2019.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Davenport & Co's 13F filing for Q3 2025, filed 15 Oct 2025.